Journal of the Practice of Cardiovascular Sciences (Jan 2017)

Cardiology update 2017: The first quarter

  • Sridharan Umapathy

DOI
https://doi.org/10.4103/jpcs.jpcs_16_17
Journal volume & issue
Vol. 3, no. 1
pp. 18 – 21

Abstract

Read online

In the first quarter of 2017, proprotein convertase subtilisin/kexin type 9's role got defined further with a number of trials such as FOURIER, ORION-1, and SPIRE 1 and 2. TAVI proves safe in intermediate-risk patients in the Surgical Replacement and Transcatheter Aortic Valve Implantation study. Newer anticoagulants extended their role to valvular heart disease. Bioabsorbable stent showed problems (ABSORB 2 and 3). New guidelines have been released for syncope and transcatheter aortic valve replacement implantation. Clinical outcome studies involving instantaneous wave-free ratio (IFR) showed IFR to be noninferior to fractional flow reserve. Optimal medical therapy proves noninferior to percutaneous coronary intervention in single vessel chronic total occlusion.

Keywords